All IndicationsMetabolic & EndocrinePhase 3Phase 3Phase 3Phase 3Phase 3Phase 2Phase 2Phase 2Phase 2
⚡
Diabetes Mellitus, Type 2
4
Companies
9
Drug Programs
5
Phase 3
0
Upcoming PDUFAs
Competitors
NVO
Novo Nordisk A/S
Insulin Glargine 100U/mL
LLY
Eli Lilly and Company
Insulin lispro mix 25
LLY
Eli Lilly and Company
Detemir
LLY
Eli Lilly and Company
Human Insulin Inhalation Powder
NVO
Novo Nordisk A/S
Insulin Icodec
JNJ
Johnson & Johnson
JNJ-41443532
LLY
Eli Lilly and Company
LY2409021
JNJ
Johnson & Johnson
JNJ16269110
AZN
AstraZeneca PLC
B - Exenatide 10 mcg twice daily
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVO Novo Nordisk A/S | Insulin Glargine 100U/mL | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Insulin lispro mix 25 | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Detemir | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Human Insulin Inhalation Powder | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | Insulin Icodec | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | JNJ-41443532 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | LY2409021 | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | JNJ16269110 | Phase 2 | — | — | — |
| AZN AstraZeneca PLC | B - Exenatide 10 mcg twice daily | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
5
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.